INNOVANCE VWF Ac assay
Explore a solution that sets a new standard in von Willebrand factor activity determination.
The INNOVANCE® VWF Ac assay is a sensitive, reliable, and convenient test system for direct, WHO-standardized determination of von Willebrand factor (VWF) activity. It is used as an aid in the diagnosis and monitoring of congenital or acquired VWF deficiencies in patients with bleeding disorders or at risk for VWF deficiency. In addition, it can be used for monitoring VWF substitution therapy. It employs an advanced new technology, allowing the assay to mimic the way in which VWF binds to glycoprotein Ib (GPIb), the major VWF receptor protein on platelets. Because the recombinant receptor protein includes two gain-of-function mutations, the assay does not require ristocetin.
Features & Benefits
Recommended screening method
A functional assay is the preferred screening method for detecting quantitative as well as qualitative defects of von Willebrand factor.1
Direct determination of VWF activity
The INNOVANCE VWF Ac assay directly determines activity of VWF. Due to the gain-of-function mutations, VWF binding to GPIb does not require ristocetin (VWF:GPIbM)2 and is therefore less susceptible to effects of certain polymorphism variants.
Excellent correlation to the gold-standard method
The INNOVANCE VWF Ac assay shows excellent correlation with the ristocetin cofactor-based BC von Willebrand Reagent assay.
Improved VWF testing workflow
The assay employs a liquid, ready-to-use reagent that requires no stirring.
Swipe through expert reviews to learn about their recent experiences
“The INNOVANCE® VWF Ac assay is reliable and precise with high sensitivity. The absence of ristocetin ensures result accuracy and minimizes the risk of misdiagnosis, especially in patients with a particular variant.”
MD, PhD, Professor of Pediatrics, Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf
Technical Specifications
Assay performance can vary from country to country as well as corresponding to the system application of the respective assay. The values listed above are provided as examples only.
INNOVANCE VWF Ac kit components
The INNOVANCE VWF Ac assay is a turbidimetric, latex-based assay that employs a liquid, ready-to-use reagent. The assay consists of three components and can be ordered as a kit.
Reagent I
Description: Buffer with polystyrene particles coated with anti-GPIb monoclonal antibodies
Available on CN-3000/6000 Systems3
Available on a broad range of analyzers
INNOVANCE VWF Ac assay applications are available on BCS® XP, CN-3000 and CN-60003, CS-2500 and CS-5100, and CA-660 Systems3. For details on ordering information and an overview of the current testing portfolio, download a copy of the hemostasis reagent catalog.
Clinical Use
Diagnostic algorithm for patients suspected of VWD1
Using functional assays in the diagnosis and monitoring of von Willebrand disease
To correctly diagnose cases involving a bleeding anamnesis or a family history of von Willebrand disease and subsequently monitor patient response to therapy, physicians require a specific test for von Willebrand factor. A functional assay is the preferred screening method for detecting quantitative as well as qualitative defects of von Willebrand factor. For more details on VWD subtypes and management, recommended lab diagnostics, and the benefits of the INNOVANCE VWF Ac assay, download the brochure.
vWF Ag assay from Siemens Healthineers
INNOVANCE VWF Ac and vWF Ag assays: Powerful components in the initial VWD testing panel
For the evaluation of von Willebrand disease, VWF activity assays can be combined with VWF antigen assays to detect and distinguish between quantitative and qualitative VWF deficiencies.1
The vWF Ag assay is an immunoturbidimetric assay that can be used on all Siemens Healthineers and Sysmex automated coagulation instruments. Explore the extended portfolio of analyzers and assays for the diagnosis of bleeding disorders and therapy monitoring.
Upgrade your bleeding diagnostics with a comprehensive portfolio of systems and assays
Expand to explore the bleeding portfolio from Siemens Healthineers
Avez-vous jugé cette information utile?
James PD, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. 2021 Jan 12 [published online].
Bodo I, et al. Platelet dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:1345–50.
Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.
In the U.S., platelet aggregation testing is for research use only, not for use in diagnostic procedures.
Credits for VWF-3D graphic:
PDB: 1SQ0
Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L. Crystal structure of the complex of the wild-type von Willebrand factor A1 domain and glycoprotein Ib alpha at 2.6 angstrom resolution. 2004. doi: 10.2210/pdb1SQ0/pdb
Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem. 2004;279:23327-34. doi: 10.1074/jbc.M401659200
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local Siemens Healthineers organization for further details.
CN Systems refers to Automated Blood Coagulation Analyzer CN-3000 and Automated Blood Coagulation Analyzer CN-6000. CN-3000 and CN-6000 Systems refer to Automated Blood Coagulation Analyzer CN-3000 and Automated Blood Coagulation Analyzer CN-6000 respectively.
CS-2500 and CS-5100 Systems refer to Automated Blood Coagulation Analyzer CS-2500 and Automated Blood Coagulation Analyzer CS-5100 respectively.